In October 2024, Alpha Pharm (Pty) Ltd. (“Alpha Pharm “), a leading South African pharmaceutical distributor and pharmacy franchisor, agreed on the majority sale to a consortium of private investors.
This acquisition is a significant milestone for Alpha Pharm, and the consortium is committed to building upon the company’s strong foundation. The consortium’s vision for Alpha Pharm includes continued growth, innovation, and a reinforced commitment to serving the South African pharmaceutical and healthcare sector.
Kroll served as exclusive M&A advisor to the majority shareholder of Alpha Pharm in connection with the transaction.
About Alpha Pharm
Headquartered in Pretoria, South Africa, Alpha Pharm is a well-established and highly regarded wholesaler and distributor of (non-)scheduled pharmaceutical products, medicines and medical devices. With a history stretching back to 1968, the Company since then has established an extensive distribution and pharmacy franchise network with more than 350 locations in total across all states in South Africa. For more information on Alpha Pharm, visit its website at https://www.alphapharmacies.co.za/.
About Kroll
As the leading independent provider of risk and financial advisory solutions, Kroll leverages unique insights, data and technology to help clients stay ahead of complex demands. Kroll’s global team continues the firm’s nearly 100-year history of trusted expertise spanning risk, governance, transactions, corporate finance and valuation. Our advanced solutions and intelligence provide clients with the foresight they need to create an enduring competitive advantage. At Kroll, our values define who we are and how we partner with clients and communities. For more information on Kroll, visit its website at https://www.kroll.com/en.
